Sign inJoin waitlistJoin the waitlist

Mitchell Shiffman

Physician · Bon Secours Richmond Community Hospital

Credentials: · · · ·

History

Bon Secours Richmond Community Hospital
Present

Gastroenterology
Medical College of Virginia Hospitals
1983–1986
Internal Medicine
Virginia Commonwealth University Health System
1980–1983
State University of New York Upstate Medical University
1979–1983

Research

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
New England Journal of Medicine · 2002 · 5,166 citations
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
The Lancet · 2001 · 5,067 citations
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group
New England Journal of Medicine · 1998 · 2,880 citations

VL
Velimir Luketic
78 papers · 2 as a fellow
Arun Sanyal
74 papers
Richard Sterling
63 papers · 2 as a fellow
GE
Gregory Everson
38 papers
RS
Richard Stravitz
34 papers
MP
Marc Posner
33 papers
Melissa Contos
33 papers · 2 as a fellow
RF
Robert Fisher
33 papers
JM
John McHutchison
28 papers
KR
Kuchikula Reddy
25 papers
AM
Alan Mills
24 papers
Eric Lawitz
24 papers

Grants

General Clinical Research Center
National Center for Research Resources · M01
Project lead · $2.5M · Virginia Commonwealth University
1997–2010
Hepatitis c Clinical Trial- Clinical Centers
National Institute of Diabetes and Digestive and Kidney Diseases · N01
Contact PI · $698.8K · Virginia Commonwealth University
1999–2007
Mucin Hypersecretion Effect on Gallbladder Physiology
National Institute of Diabetes and Digestive and Kidney Diseases · R29
Contact PI · $512.7K · Virginia Commonwealth University
1991–1996

Clinical trials

A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)
Principal investigator · Unknown · Phase 4
Liver Institute of Virginia
2013–2015
Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics
Principal investigator · Terminated
Meridian Bioscience, Inc.
2008–2011
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients
Principal investigator · Completed · Phase 2
Romark Laboratories L.C.
2008–2010
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C
Principal investigator · Completed · Phase 2
Romark Laboratories L.C.
2007–2010